Mitomycin C, Streptomyces caespitosus, Carrier-Free

Name: Mitomycin C, <i>Streptomyces caespitosus</i>, Carrier-Free
Brand: MM

Antibiotic and carcinostatic agent. Inhibits DNA synthesis by cross-linking DNA at guanine and adenine residues; disrupts base pairing. Induces apoptosis in gastric cancer cells.

Synonym(s):

Mitomycin C, Streptomyces caespitosus, Carrier-Free, Mitocin C, MMC

Select a Size

All Photos(1)

About This Item

Empirical Formula (Hill Notation):

C₁₅H₁₈N₄O₅

CAS Number:

50-07-7

Molecular Weight:

334.33

UNSPSC Code:

12352200

MDL number:

MFCD00078109

Product Name

Mitomycin C, Streptomyces caespitosus, Carrier-Free, Antibiotic and carcinostatic agent. Inhibits DNA synthesis by cross-linking DNA at guanine and adenine residues; disrupts base pairing. Induces apoptosis in gastric cancer cells.

InChI

1S/C15H18N4O5/c1-5-9(16)12(21)8-6(4-24-14(17)22)15(23-2)13-7(18-13)3-19(15)10(8)11(5)20/h6-7,13,18H,3-4,16H2,1-2H3,(H2,17,22)/t6-,7+,13+,15-/m1/s1

InChI key

NWIBSHFKIJFRCO-WUDYKRTCSA-N

assay

≥95% (HPLC)

form

solid

manufacturer/tradename

Calbiochem^®

storage condition

OK to freeze
protect from light

color

purple

solubility

water: <1 mg/mL
methanol: 5 mg/mL

shipped in

ambient

storage temp.

2-8°C

Quality Level

100

Biochem/physiol Actions

Potency: ≥ 970 μg/mg mitomycin C

Disclaimer

Toxicity: Highly Toxic & Carcinogenic / Teratogenic (I)

General description

Antibiotic and carcinostatic agent. Inhibits DNA synthesis by cross-linking DNA at guanine and adenine residues; disrupts base pairing. Induces apoptosis in gastric cancer cells. Blocks the cell cycle at the G₂ phase. Potency: ≥970 µg/mg.

Other Notes

Due to the nature of the Hazardous Materials in this shipment, additional shipping charges may be applied to your order. Certain sizes may be exempt from the additional hazardous materials shipping charges. Please contact your local sales office for more information regarding these charges.

Kryt, F.A., et al. 1996. Blood 89, 938.
Schwartz, G.K., et al. 1995. J. Natl. Cancer Inst. 87, 1394.
Folnan, R.S., 1993. Oncology 50, 24.
Tomasz, M., et al. 1987. Science 235, 1204.

Preparation Note

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

pictograms

GHS06,GHS08

signalword

Danger

hcodes

H300,H351

pcodes

P202 - P264 - P270 - P280 - P301 + P310 - P405

Hazard Classifications

Acute Tox. 2 Oral - Carc. 2

Storage Class

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Identification and pre-clinical investigation of 3-O-cyclohexanecarbonyl-11-keto-β-boswellic acid as a drug for external use to treat psoriasis.

Fangzhou Lou et al.

British journal of pharmacology, 181(8), 1290-1307 (2023-09-26)

Psoriasis vulgaris is a refractory skin inflammatory disorder with 80% of the cases belonging to the mild-to-moderate type, which can be controlled by topical treatment. Nevertheless, the drugs for external use have not been upgraded for decades. We modified acetyl-11-keto-beta-boswellic

FANCM regulates repair pathway choice at stalled replication forks.

Arvind Panday et al.

Molecular cell, 81(11), 2428-2444 (2021-04-22)

Repair pathway "choice" at stalled mammalian replication forks is an important determinant of genome stability; however, the underlying mechanisms are poorly understood. FANCM encodes a multi-domain scaffolding and motor protein that interacts with several distinct repair protein complexes at stalled

CYB561 supports the neuroendocrine phenotype in castration-resistant prostate cancer.

Romie Angelo G Azur et al.

PloS one, 19(5), e0300413-e0300413 (2024-05-13)

Castration-resistant prostate cancer (CRPC) is associated with resistance to androgen deprivation therapy, and an increase in the population of neuroendocrine (NE) differentiated cells. It is hypothesized that NE differentiated cells secrete neuropeptides that support androgen-independent tumor growth and induce aggressiveness

Fatty acids abrogate the growth-suppressive effects induced by inhibition of cholesterol flux in pancreatic cancer cells.

Yuchuan Li et al.

Cancer cell international, 23(1), 276-276 (2023-11-18)

Despite therapeutic advances, the prognosis of pancreatic ductal adenocarcinoma (PDAC) remains extremely poor. Metabolic reprogramming is increasingly recognized as a key contributor to tumor progression and therapy resistance in PDAC. One of the main metabolic changes essential for tumor growth